» Authors » Priyanka D Patel

Priyanka D Patel

Explore the profile of Priyanka D Patel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 112
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nampota-Nkomba N, Nyirenda O, Datta S, Mapemba V, Patel P, Misiri T, et al.
EClinicalMedicine . 2025 Mar; 81:103100. PMID: 40034570
Background: We assessed persistence of typhoid immunity conferred by Vi polysaccharide-tetanus toxoid (Vi-TT) conjugate vaccine (TCV) four years post-vaccination and immunogenicity of a booster dose of Vi-TT given at age...
2.
Nampota-Nkomba N, Nyirenda O, Mapemba V, Masonga R, Patel P, Misiri T, et al.
Hum Vaccin Immunother . 2024 Sep; 20(1):2384760. PMID: 39263923
Vaccine safety and immunogenicity data in human immunodeficiency virus (HIV)-exposed uninfected (HEU) children are important for decision-making in HIV and typhoid co-endemic countries. In an open-label study, we recruited Malawian...
3.
Neuzil K, Patel P, Ndeketa L, Laurens M, Gordon M
Lancet . 2024 Aug; 404(10454):748. PMID: 39181588
No abstract available.
4.
Mallepeddi S, Patel P, DAmico C, Thiessen C
Transplant Proc . 2024 Jul; 56(6):1216-1221. PMID: 39013745
Background: Solid organ transplantation improves the quality of life for patients but has significant out-of-pocket expenses for donors and recipients in the USA, leading many to utilize crowdfunding for donations...
5.
Ashton P, Chunga Chirambo A, Meiring J, Patel P, Mbewe M, Silungwe N, et al.
Lancet Microbe . 2024 Feb; 5(3):e226-e234. PMID: 38387472
Background: Ciprofloxacin is the first-line drug for treating typhoid fever in many countries in Africa with a high disease burden, but the emergence of non-susceptibility poses a challenge to public...
6.
Patel P, Liang Y, Meiring J, Chasweka N, Patel P, Misiri T, et al.
Lancet . 2024 Jan; 403(10425):459-468. PMID: 38281499
Background: Randomised controlled trials of typhoid conjugate vaccines among children in Africa and Asia have shown high short-term efficacy. Data on the durability of protection beyond 2 years are sparse....
7.
Liang Y, Driscoll A, Patel P, Datta S, Voysey M, French N, et al.
Lancet Glob Health . 2022 Nov; 11(1):e136-e144. PMID: 36442498
Background: Typhoid conjugate vaccines are being introduced in low-income and middle-income countries to prevent typhoid illness in children. Vaccine effectiveness studies assess vaccine performance after introduction. The test-negative design is...
8.
Limani F, Smith C, Wachepa R, Chafuwa H, Meiring J, Noah P, et al.
PLoS One . 2022 Nov; 17(11):e0277419. PMID: 36417455
Background: Typhoid causes preventable death and disease. The World Health Organization recommends Typhoid Conjugate Vaccine for endemic countries, but introduction decisions depend on cost-effectiveness. We estimated household and healthcare economic...
9.
Nampota-Nkomba N, Nyirenda O, Khonde L, Mapemba V, Mbewe M, Ndaferankhande J, et al.
Lancet Glob Health . 2022 Aug; 10(9):e1326-e1335. PMID: 35961356
Background: Typhoid fever is a substantial public health problem in Africa, yet there are few clinical trials of typhoid conjugate vaccine (TCV). We assessed immunogenicity and safety of Typbar TCV...
10.
Mvaya L, Khaba T, Lakudzala A, Nkosi T, Jambo N, Kadwala I, et al.
JCI Insight . 2022 Feb; 7(3). PMID: 35132966
The duodenum is a major site of HIV persistence during suppressive antiretroviral therapy despite harboring abundant tissue-resident memory (Trm) CD8+ T cells. The role of duodenal Trm CD8+ T cells...